| Code | CSB-RA018727MB1HU |
| Size | |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar referenced to the antibody described in patent US 2016/0319029A1, targeting PRLR (prolactin receptor). PRLR is a type I cytokine receptor that mediates the actions of prolactin, a hormone essential for mammary gland development and lactation but also implicated in oncogenesis. PRLR is expressed in multiple tissues including breast, prostate, ovarian, and pancreatic tissues, where it activates JAK2-STAT5, MAPK, and PI3K-AKT signaling pathways. These pathways promote cell proliferation, survival, migration, and chemotherapy resistance. PRLR is overexpressed in approximately 25% of breast cancers and is also elevated in prostate, ovarian, endometrial, and pancreatic cancers, where it contributes to tumor progression and poor prognosis. The reference antibody is designed to neutralize PRLR signaling by blocking prolactin binding and receptor activation. This biosimilar provides researchers with a valuable tool for investigating prolactin-PRLR axis biology, studying hormone-driven tumor growth mechanisms, and exploring therapeutic strategies targeting PRLR in preclinical cancer models. It supports research into PRLR-mediated signaling pathways, autocrine/paracrine prolactin effects, and the role of this receptor in chemotherapy resistance and metastasis.
There are currently no reviews for this product.